Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American International Group Inc (AIG) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

American International Group IncTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

American International Group Inc vs Inovio Pharmaceuticals Inc — how do they compare? American International Group Inc trades at $76.68 (market cap $40.42B), while Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M). The key difference: American International Group Inc is far larger — about 514.6× Inovio Pharmaceuticals Inc's market cap, and American International Group Inc pays a 2.59% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AIGINO
Market Cap
$40.42B$78.55M
Sector
FinancialsHealth
52-Week High
$86.59$2.87
52-Week Low
$71.89$0.66
Enterprise Value
$48.06B$49.56M
Dividend Yield
2.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American International Group Inc

AIG trades at $77.61, down 1.49% today, with a bearish technical signal but strong fundamental performance. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $2.00 exceeding the $1.92 estimate. The company maintains solid profitability with an 11.12% net income margin and a P/E of 14.11, indicating reasonable valuation. Cash flow from operations remains positive at $3.31 billion for 2025, supporting dividend payments of $0.50 per share.

The outlook is mixed; analyst consensus is a Buy with a $89.00 price target, suggesting 14.7% upside, but technical indicators signal near-term caution. Risks include competitive pricing pressure and geopolitical exposures, while opportunities lie in disciplined underwriting and AI integration. Investor sentiment is cautiously optimistic amid steady premium growth and expense control.

Inovio Pharmaceuticals Inc

INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.

Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.

Returns comparison

Trailing returns across standard periods

About American International Group Inc

American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.

Read more on AIG

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO